Search
Displaying 281–290 of 556 for “Retinitis pigmentosa”
-
Bionic Sight’s Optogenetic Therapy Enables Blind Patients to Detect Light and Motion in Early Trial
Research NewsThe approach holds potential for restoring vision to people with little or no vision
-
ProQR’s RNA Therapy for USH2A Performs Well in Phase 1/2 Clinical Trial
Research NewsThe company is planning two Phase 2/3 clinical trials for the treatment
-
Beacon Stories
18-year-old Marty Dubecky has a very unique decision to make. There are currently four gene therapy clinical trials for him to choose from to enroll in, which would have been unheard of 15 years ago when he was first diagnosed with XLRP.
-
George Dolan: Cherished Friend and Community Advocate
Beacon StoriesGeorge was well-known in his community for his integrity and dedication to helping everyone around him.
-
Managing Your Mindset, Embracing Your Voice
WellnessCharity’s recent rapid decline in vision due to RP and her daughter’s diagnosis with RP has caused her to open up about her vision loss journey. After getting involved with the Foundation, Charity now feels like she has a voice to help others in the visually impaired community.
-
A Eureka Moment for Paul Yang Boosts Advancement of Vision-Saving RP Drug
Research NewsHis latest Foundation grant is helping move the drug toward a clinical trial
-
ProQR Completes Enrollment in Phase 2/3 Clinical Trial of RNA Therapy for LCA10
Research NewsCompany also announced progress in enrollment for Phase 1 / 2 clinical trials for emerging USH2A and RHO RNA therapies.
-
Penn Vet’s William Beltran Elected to the National Academy of Medicine
Research NewsThe veterinary researcher’s canine studies are advancing promising retinal therapies toward clinical trials
-
Partner News
Acquisition significantly expands Janssen’s eye disease portfolio and strengthens its gene therapy capabilities. Late-stage AMD affects millions of people with no effective treatments currently available .
-
AGTC Announces Results for Achromatopsia Gene Therapy Clinical Trials
Research NewsThe company will continue enrolling younger patients in higher dosing groups.
